홈 › 만성 림프구성 백혈병 › 매사추세츠
매사추세츠의 만성 림프구성 백혈병 임상 시험
만성 림프구성 백혈병 관련 연구 33개가 매사추세츠 내 여러 지역에서 참여자를 모집하고 있습니다.
매사추세츠의 도시
공식 연구 텍스트(영어)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Dana-Farber Cancer Institute, Boston
피험자 모집 중3상
65세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT07321652Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Tufts Medical Center Cancer Center Stoneham, Stoneham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06943872A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05006716A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Dana Farber Cancer Institute, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07277231A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Dana Farber Cancer Institute, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06973187Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT07061951A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06564038Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Tufts Medical Center, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT03666000Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT04588922Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT07426484Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
- Massachusetts General Hospital, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT06849713Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
- Research Site, Boston
피험자 모집 중2상
18세 ~ 130세 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07024706A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
피험자 모집 중1상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 7. 28. 업데이트됨 · NCT07020533A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Boston Medical Center, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 5. 19. 업데이트됨 · NCT06588478Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- 외 2개
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 5. 7. 업데이트됨 · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
13세 이상 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04771572Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
- Dana-Farber Cancer Institute, Boston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 4. 24. 업데이트됨 · NCT00131014Understanding Chronic Lymphocytic Leukemia
- Dana Farber Cancer Institute, Boston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 4. 24. 업데이트됨 · NCT04028531A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- UMass Memorial Medical Center /ID# 270023, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 4. 9. 업데이트됨 · NCT06428019CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
피험자 모집 중2상건강한 지원자 환영
18세 ~ 75세 · 모든 성별 · 2026. 3. 10. 업데이트됨 · NCT06059391A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Dana-Farber Cancer Institute, Boston
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 3. 2. 업데이트됨 · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Dana-Farber Cancer Institute, Boston
피험자 모집 중4상
18세 이상 · 모든 성별 · 2026. 3. 2. 업데이트됨 · NCT06876649Study of SGR-1505 in Mature B-Cell Neoplasms
- Beth Israel Deaconess Medical Center, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 13. 업데이트됨 · NCT05544019Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 2. 11. 업데이트됨 · NCT06644183Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Dana-Farber Cancer Institute /ID# 230061, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 2. 9. 업데이트됨 · NCT04895436Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
- Beth Israel Deaconess Medical Center, Boston
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 1. 21. 업데이트됨 · NCT06333262Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 1. 7. 업데이트됨 · NCT06043674Mosunetuzumab for CLL MRD Clearance
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 12. 15. 업데이트됨 · NCT07052695AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- University of Massachusetts Memorial Medical Center, Worcester
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 12. 10. 업데이트됨 · NCT05602363Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- South Shore Hospital, South Weymouth
피험자 모집 중2상
18세 이상 · 모든 성별 · 2025. 12. 5. 업데이트됨 · NCT05168930CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 7. 17. 업데이트됨 · NCT04704323ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.